Literature DB >> 11447843

Presenilin function: connections to Alzheimer's disease and signal transduction.

P E Fraser1, G Yu, L Lévesque, M Nishimura, D S Yang, H T Mount, D Westaway, P H St George-Hyslop.   

Abstract

Missense mutations in presenilin 1 (PS1) and presenilin 2 (PS2) are associated with early-onset familial Alzheimer's disease which displays an accelerated deposition of amyloid plaques and neurofibrillary tangles. Presenilins are multi-spanning transmembrane proteins which localize primarily to the endoplasmic reticulum and the Golgi compartments. We have previously demonstrated that PS1 exists as a high-molecular-mass complex that is likely to contain several functional ligands. Potential binding proteins were screened by the yeast two-hybrid system using the cytoplasmically orientated PS1 loop domain which was shown to interact strongly with members of the armadillo family of proteins, including beta-catenin, p0071 and a novel neuron-specific plakophilin-related armadillo protein (NPRAP). Armadillo proteins can have dual functions that encompass the stabilization of cellular junctions/synapses and the mediation of signal transduction pathways. Our observations suggest that PS1 may contribute to both aspects of armadillo-related pathways involving neurite outgrowth and nuclear translocation of beta-catenin upon activation of the wingless (Wnt) pathway. Alzheimer's disease (AD)-related presenilin mutations exhibit a dominant gain of aberrant function resulting in the prevention of beta-catenin translocation following Wnt signalling. These findings indicate a functional role for PS1 in signalling and suggest that mistrafficking of selected presenilin ligands may be a potential mechanism in the genesis of AD.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11447843     DOI: 10.1042/bss0670089

Source DB:  PubMed          Journal:  Biochem Soc Symp        ISSN: 0067-8694


  9 in total

1.  Defects of immune regulation in the presenilin-1 mutant knockin mouse.

Authors:  Grant A Morgan; Qing Guo; Sic L Chan; Devin S Gary; Barbara A Osborne; Mark P Mattson
Journal:  Neuromolecular Med       Date:  2007       Impact factor: 3.843

Review 2.  Brain metabolic dysfunction at the core of Alzheimer's disease.

Authors:  Suzanne M de la Monte; Ming Tong
Journal:  Biochem Pharmacol       Date:  2013-12-28       Impact factor: 5.858

3.  Specific inhibition of CBP/beta-catenin interaction rescues defects in neuronal differentiation caused by a presenilin-1 mutation.

Authors:  Jia-Ling Teo; Hong Ma; Cu Nguyen; Crystal Lam; Michael Kahn
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-10       Impact factor: 11.205

Review 4.  Type 3 diabetes is sporadic Alzheimer׳s disease: mini-review.

Authors:  Suzanne M de la Monte
Journal:  Eur Neuropsychopharmacol       Date:  2014-06-28       Impact factor: 4.600

Review 5.  Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease.

Authors:  Suzanne M de la Monte
Journal:  Drugs       Date:  2012-01-01       Impact factor: 9.546

Review 6.  Therapeutic targets of brain insulin resistance in sporadic Alzheimer's disease.

Authors:  Suzanne M de la Monte
Journal:  Front Biosci (Elite Ed)       Date:  2012-01-01

Review 7.  Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease.

Authors:  Suzanne M de la Monte
Journal:  Curr Alzheimer Res       Date:  2012-01       Impact factor: 3.498

8.  CSF and Brain Indices of Insulin Resistance, Oxidative Stress and Neuro-Inflammation in Early versus Late Alzheimer's Disease.

Authors:  Sarah Lee; Ming Tong; Steven Hang; Chetram Deochand; Suzanne de la Monte
Journal:  J Alzheimers Dis Parkinsonism       Date:  2013-10-31

Review 9.  Mechanisms linking brain insulin resistance to Alzheimer's disease.

Authors:  Maria Niures P S Matioli; Ricardo Nitrini
Journal:  Dement Neuropsychol       Date:  2015 Apr-Jun
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.